文献速递MDS 与骨髓增殖性肿瘤白血病

U2af1S34F与U2af1Q157R热点突变诱导小鼠不同造血表型

U2af1S34F and U2af1Q157R myeloid neoplasm-associated hotspot mutations induce distinct hematopoietic phenotypes in mice.
PubMed 文献 · Leukemia · 2026-05-06

本研究在小鼠体内表达U2AF1的两个热点突变S34F和Q157R,发现二者诱导不同的造血表型:表达U2af1S34F的小鼠较表达U2af1Q157R的小鼠出现更严重的血细胞和骨髓细胞计数下降及干细胞再增殖能力降低。两突变靶基因的表达和剪接模式在鼠和人样本中大多独特,且与不同基因突变共现并在不同髓系肿瘤中分布不均,提示不应将二者混为一谈。

要点

  • U2af1S34F小鼠较Q157R小鼠造血下降更重、干细胞再增殖能力更差。
  • 两突变靶基因表达与剪接模式在鼠和人样本中大多独特,可能驱动表型差异。
  • 两突变与不同基因突变共现且在各髓系肿瘤中分布不均,发病机制可能多样。

核心结论

  • U2AF1S34F和U2AF1Q157R突变在体内诱导不同的造血、基因表达和RNA剪接表型。
  • 两突变不应被混为一谈,可能以不同方式影响患者疾病发病机制。
  • 需更大人群研究确定这些表型变化是否转化为临床病理差异,以支持分开分类。

研究设计与样本

  • 研究通过小鼠体内表达U2AF1两个热点突变(S34F和Q157R)来表征其后果。

主要发现

  • 表达U2af1S34F的小鼠较表达U2af1Q157R的小鼠血液和骨髓细胞计数下降更严重,干细胞再增殖能力降低。
  • 两突变靶基因的表达和剪接在鼠和人样本中大多独特,可能驱动表型差异。
  • 两突变在患者中与不同基因突变共现,且在各髓系肿瘤中分布不均。

临床怎么用

  • 临床解读U2AF1突变时应区分S34F和Q157R,不宜等同处理。
  • 两突变与不同共现突变及肿瘤类型分布不均,提示需按突变亚型评估疾病机制。

局限性

  • 需更大人群研究确定小鼠表型变化是否转化为患者临床病理差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recurrent somatic mutations in the spliceosome genes SF3B1, SRSF2, and U2AF1 are frequently identified in patients with myeloid neoplasms, such as myelodysplastic syndromes. We characterized the in vivo consequences of expressing two hotspot mutations in U2AF1 that code for the S34F and Q157R substitutions. Our results indicate that the two mutations induce distinct hematopoietic phenotypes in mice, suggesting that the U2AF1S34F and U2AF1Q157R mutations should not be conflated as they may impact disease pathogenesis differently in patients. Mice expressing U2af1S34F have a more severe reduction in their blood and bone marrow cell counts and reduced stem cell repopulating ability, compared to mice expressing U2af1Q157R. The expression and splicing of target genes are largely unique between the mutations, in both mouse and human samples, potentially driving the phenotypic differences induced by either mutation. The two mutations co-occur with different gene mutations in patients and are not equally represented across myeloid neoplasms, suggesting that multiple mechanisms likely drive U2AF1-mutant disease pathogenesis. Collectively, our results support that U2AF1S34F and U2AF1Q157R mutations induce distinct hematopoietic, gene expression, and RNA splicing phenotypes in vivo. Larger population studies will be needed to determine if these phenotypic changes translate into clinico-pathologic differences in patients, warranting separate classification.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Alberti MO, Nonavinkere Srivatsan S, Shao J, et al. U2af1S34F and U2af1Q157R myeloid neoplasm-associated hotspot mutations induce distinct hematopoietic phenotypes in mice. Leukemia. 2026. PMID: 42092046. doi:10.1038/s41375-026-02974-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。